Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Exactly, some folks are acting like the stock will never recover. If the trials continue to generate positive data, which they have for the most part, the stock will recover from the ridiculously low valuation we are at. While on one hand, the timing and literally all time low price that Lombardo did this dilution does not reflect highly on his management, on the other hand he is facing the hurdle of trying to turn around a company that was badly mismanaged over the last four years so the market generally does not trust ADXS given the history.